1 company-specific change
fiscal period 2025-12-31
filed 2026-02-18
- Outstanding options surged from 2.0M to 137.9M shares—a 68x increase. This massive dilution risk materially worsens shareholder value and capital structure.
See the full detail →
3 company-specific changes
fiscal period 2025-12-31
filed 2026-02-18
- Added specific 2025 tariff escalation and retaliatory tariffs with documented supply chain cost impact, moving from hypothetical to realized risk.
- Added specific dependency on large engines for data center backup applications, a material new product line exposure to supply chain risk.
See the full detail →
6 company-specific changes
fiscal period 2025-12-31
filed 2026-02-18
- Removal of detailed offshore operations risk disclosure, including Gulf of America deep-water vulnerabilities, hurricanes, equipment failure, and regulatory compliance risks. Suggests material reduction in offshore exposure or risk profile.
- OxyChem Transaction completion materially increases commodity price exposure. New disclosure of heightened vulnerability to oil, NGL, natural gas volatility post-acquisition.
See the full detail →
14 company-specific changes
fiscal period 2025-12-31
filed 2026-02-17
- SEC investigation into accounting errors resolved and disclosed; removal signals closure of material compliance matter and reduced regulatory/reputational risk.
- Material SEC/DOJ investigations into intersegment sales were disclosed last year with risk of fines, injunctions, and penalties. Removal suggests investigations concluded or were resolved without material adverse outcome.
See the full detail →
4 company-specific changes
fiscal period 2025-12-31
filed 2026-02-17
- New disclosure of active divestiture (SmartDose sale to AbbVie) and ongoing M&A strategy. Concrete transaction risk with material operational and financial consequences.
- New disclosure of material customer concentration risk. Loss of key customers could materially impact revenue and financial condition—a substantive business risk.
See the full detail →
4 company-specific changes
fiscal period 2025-12-31
filed 2026-02-17
- Added concrete 2026 outage example showing actual service disruption materialized. New disclosure of litigation and governmental investigation risks from operational failures.
- Unsecured debt increased $13.2B (11.2%) to $131.1B; secured debt rose $1.0B. Debt burden materially worsened year-over-year.
See the full detail →
14 company-specific changes
fiscal period 2025-12-31
filed 2026-02-17
- Resideo indemnification agreement terminated; Honeywell received $1.59B one-time payment, eliminating future environmental reimbursement obligations. Material liquidity improvement.
- New disclosure of capital market access risk and funding constraints, particularly around Separation. Adds substantive liquidity and refinancing concerns beyond prior counterparty credit focus.
See the full detail →
5 company-specific changes
fiscal period 2025-12-31
filed 2026-02-17
- Restructuring charges increased 56% ($450-550M to $700-800M) and expected savings increased 56% ($225-275M to $350-400M), signaling material escalation in program scope and financial impact.
- New disclosure of site-of-care migration risk (inpatient to outpatient/ASC/office-based) with impacts on reimbursement, pricing, and provider economics—a substantive market structural shift.
See the full detail →
3 company-specific changes
fiscal period 2025-12-31
filed 2026-02-17
- Added explicit disclosure of direct-to-dealer channel dependency and new competitive threat from low-barrier distribution entrants, escalating revenue and market-share risk.
- Warranty liability increased 5.5% ($158.4M to $167.2M) year-over-year. Company also discontinued lifetime warranties, suggesting prior exposure materialized or was reassessed.
See the full detail →
11 company-specific changes
fiscal period 2025-12-31
filed 2026-02-17
- Company disclosed a $6.7 billion goodwill impairment charge in Q3 2025 due to market conditions and stock price decline, materially worsening the risk profile.
- Risk escalated materially: new specific 2025 examples of higher-than-expected morbidity, Medicaid medical costs, and behavioral health expenses; added language on rate adjustment delays and premium deficiency reserves.
See the full detail →
11 company-specific changes
fiscal period 2025-12-31
filed 2026-02-17
- Reserve replacement fell sharply from 244% to 80%, driven by noncore asset dispositions and lower prices. Organic replacement also declined from 123% to 99%, indicating weakened reserve replenishment capacity.
- New disclosure of restructuring with severance costs in Alaska segment. Net income fell 45% ($1,326M to $730M) year-over-year, with $151M higher operating expenses including severance.
See the full detail →
4 company-specific changes
fiscal period 2026-01-02
filed 2026-02-17
- New executive order imposes material restrictions on buybacks, dividends, and executive compensation tied to performance metrics. Secretary of War enforcement authority and 15-day remediation requirements create new compliance obligations and financial constraints.
- Expanded negative publicity risk to include "sustained or recurring media coverage" and industry-wide criticism, plus new vulnerabilities around "investment, prioritization, and production" deficiencies.
See the full detail →
6 company-specific changes
fiscal period 2025-12-31
filed 2026-02-17
- Removal of material supply chain constraint risk. Prior year disclosed significant semiconductor/component shortages, cost pressures, and revenue/margin impacts. Deletion signals material improvement in supply conditions.
- Purchase obligations nearly doubled from $130.9M to $252.3M, materially increasing supply chain concentration risk and financial exposure to contract manufacturer disruptions.
See the full detail →
10 company-specific changes
fiscal period 2025-12-31
filed 2026-02-17
- Added specific disclosure of increased purchase commitments tied to AI deployment and memory market tightening, escalating working capital risk and inventory exposure.
- New disclosure of geopolitical-driven regulatory barriers tied to China sourcing, affecting product approvals and market access globally. Substantive operational and revenue risk.
See the full detail →
11 company-specific changes
fiscal period 2025-12-31
filed 2026-02-17
- Removal of IP infringement risk disclosure signals reduced exposure to costly litigation, injunctions, and indemnification claims that previously posed material adverse impact.
- Removal of material operational risk regarding contract underpricing, cost overruns, and change order delays in R&D Solutions business. Suggests improved pricing discipline or reduced exposure.
See the full detail →
2 company-specific changes
fiscal period 2025-12-31
filed 2026-02-17
- New $182M impairment charge in Q4 2025 disclosed; prior year cited $125M + $111M goodwill/intangible charges. Escalated materiality of impairment risk.
- New disclosure of specific restructuring initiatives (Network Reconfiguration, Efficiency Reimagined) involving facility consolidations and workforce reductions, escalating from generic labor-cost control language to concrete restructuring risk.
See the full detail →
3 company-specific changes
fiscal period 2025-12-31
filed 2026-02-17
- New disclosure of material AI deployment risks across critical operations (forecasting, grid planning, asset management). Identifies concrete risks: inaccuracy, regulatory penalties, litigation, service disruptions, reputational harm.
- New disclosure of customer affordability pressures limiting cost recovery, heightened political scrutiny, and competitive transmission solicitation risks with potential ROE reductions.
See the full detail →
1 company-specific change
fiscal period 2025-12-31
filed 2026-02-17
- Hedging effectiveness reversed: $563M favorable mark-to-market in 2024 became $491M unfavorable in 2025, a $1.054B swing materially worsening cost exposure.
See the full detail →
1 company-specific change
fiscal period 2025-12-31
filed 2026-02-17
- Restructuring charges increased 65% year-over-year ($51.4M vs $31.2M), signaling escalated restructuring activity and higher near-term costs.
See the full detail →
12 company-specific changes
fiscal period 2025-12-31
filed 2026-02-17
- Removal of material acquisition risk factors indicates transaction completed or abandoned. Resolves significant M&A execution and integration uncertainty disclosed prior year.
- Removal of major M&A risk factor indicates transaction completed or abandoned. Material change in strategic risk profile for investors.
See the full detail →
10 company-specific changes
fiscal period 2025-12-31
filed 2026-02-17
- Removal of major strategic separation risk. Intended Electronics Separation no longer disclosed as material risk, indicating transaction abandoned or substantially de-risked.
- New disclosure of material divestiture risk. Aramids sale expected Q1 2026 with regulatory, timing, and operational separation uncertainties that could impact value and results.
See the full detail →
2 company-specific changes
fiscal period 2025-12-31
filed 2026-02-13
- New material regulatory developments: OB3 enacted July 2025 affecting Medicare/Medicaid; MFN Executive Order and July 2025 letter requiring pricing concessions; Colorado PDAB set ENBREL UPL substantially below cost effective Jan 2027; Otezla now subject to Medicare price setting effective Jan 2027; Washington PDAB reviewing ENBREL. Company announced December 2025 acceptance of MFN pricing terms. These represent concrete, adverse policy changes with quantified near-term impacts on major products.
- Substantially expanded disclosure of supply chain risks, including new specific examples (Horizon CMOs, TEPEZZA/KRYSTEXXA single-source suppliers in Israel affected by Middle East conflict), PFAS regulatory threats, and tariff impacts. Risk escalated in detail and severity.
See the full detail →
6 company-specific changes
fiscal period 2025-12-31
filed 2026-02-13
- New 2025 rate agreement increases base revenue requests by $1.65B (2026-2027) versus prior $1.25B (2022-2023), higher authorized ROE (10.95% vs 10.60%), and introduces new tariffs for large-load customers, materially expanding regulatory obligations and cost recovery mechanisms.
- New disclosure of substantial rate-regulated transmission and natural gas pipeline assets with FERC/state jurisdiction exposure, creating material regulatory and operational risk.
See the full detail →
1 company-specific change
fiscal period 2025-12-31
filed 2026-02-13
- New disclosure of September 2025 mud rush incident at PTFI Grasberg mine with phased restart/ramp-up impact on production, sales, and operations—material operational disruption.
See the full detail →
8 company-specific changes
fiscal period 2025-12-31
filed 2026-02-13
- Removal of detailed Medicaid rebate and 340B program compliance risk. Company explicitly eliminated disclosure of material regulatory exposure affecting pricing, rebates, and revenue.
- New disclosure of significantly higher manufacturing costs as percentage of revenue compared to CF medicines, indicating operational and margin pressure on CASGEVY commercialization.
See the full detail →
3 company-specific changes
fiscal period 2025-12-31
filed 2026-02-13
- New specific disclosure of 2025 U.S. tariff impacts on Global Forwarding business, including actual Q2 volume declines and operational disruptions. Escalates from generic tariff risk to realized material business impact.
- Top 100 customers' revenue concentration increased from 34% to 40%, indicating heightened customer concentration risk and greater vulnerability to customer loss.
See the full detail →
6 company-specific changes
fiscal period 2025-12-31
filed 2026-02-13
- SEC investigation concluded without enforcement action. Material risk reduction from ongoing investigation uncertainty to formal closure.
- Added load-shedding risk and expanded cost drivers (credit support, minimum demand charges, tariff changes). Escalates power supply vulnerability and cost exposure.
See the full detail →
1 company-specific change
fiscal period 2025-12-31
filed 2026-02-13
- Lease mark-to-market declined from 30% to 18%, indicating reduced upside potential. However, 2025 rent growth of 50% shows strong near-term execution offsetting longer-term headwinds.
See the full detail →
5 company-specific changes
fiscal period 2025-12-31
filed 2026-02-13
- New disclosure of material refinancing risk: $1.1B debt maturing 2026-2027 faces elevated refinancing costs if rates remain high, directly impacting liquidity and cost of capital.
- Removal of material interest-rate risk disclosure. Prior year flagged elevated rates' impact on borrowing costs, asset valuations, and equity capital access. Deletion signals management's view that this acute risk has moderated.
See the full detail →
10 company-specific changes
fiscal period 2025-12-31
filed 2026-02-13
- Material new disclosure: $107M restructuring charges in 2025, headcount reductions, $60M expected in 2026. Substantive workforce action.
- $147M intangible impairment charge on trade names is material. Signals asset value deterioration and reduced earnings; investors and creditors would act on this.
See the full detail →
2 company-specific changes
fiscal period 2025-12-31
filed 2026-02-13
- Removal of seed capital/co-investment loss risk disclosure. Material easing if company no longer holds significant seed capital or has resolved prior impairment concerns.
- Added explicit competitive threat from AI-driven investment managers with lower-cost solutions and new operational control requirements, escalating business impact beyond prior regulatory/technical risks.
See the full detail →
1 company-specific change
fiscal period 2025-12-31
filed 2026-02-13
- Total debt increased 37.5% from $4.0B to $5.5B year-over-year, materially worsening leverage and financial risk profile.
See the full detail →
2 company-specific changes
fiscal period 2025-12-31
filed 2026-02-13
- Removal of NFP integration risk disclosure indicates integration substantially complete or concluded. Material easing of previously disclosed M&A execution and cost realization risk.
- Debt reduced from $17.0B to $15.2B (10.6% decrease), easing leverage risk. However, new covenant compliance language added, slightly offsetting the improvement.
See the full detail →
6 company-specific changes
fiscal period 2025-12-31
filed 2026-02-13
- New disclosure of private credit market risks: interconnectivity, non-bank lender stress, weaker underwriting, liquidity concerns, and contagion to JPMorganChase's wholesale businesses.
- New explicit disclosure of counterparty fraud risk in collateral accounting and reporting, with stated past losses and future impact on financial condition.
See the full detail →
1 company-specific change
fiscal period 2025-12-31
filed 2026-02-12
- New $1.8B acquisition risk disclosed. Material transaction with regulatory, financing, integration, and synergy realization uncertainties that could adversely affect financial condition.
See the full detail →
8 company-specific changes
fiscal period 2025-12-31
filed 2026-02-12
- Revised disclosure escalates execution risks, adds data center demand, and introduces material financing uncertainty—capital markets access constraints could impair ability to fund infrastructure expansion.
- Removal of risk tied to announced asset sales (IMTCo/OHTCo noncontrolling interest) suggests transaction completed or abandoned, materially reducing prior uncertainty about cash flows and financial condition.
See the full detail →
3 company-specific changes
fiscal period 2025-12-31
filed 2026-02-12
- New dedicated risk factor on generative AI deployment in underwriting and claims, introducing novel risks: model bias, IP infringement, regulatory uncertainty, and unknown hazards from emerging technology.
- Added explicit disclosure that certain investments have contractual restrictions limiting ability to sell or dispose. New language on stressed/distressed scenarios escalates liquidity risk severity.
See the full detail →
3 company-specific changes
fiscal period 2025-12-31
filed 2026-02-12
- New business entry into solar sector introduces material execution, regulatory, and supply-chain risks. Dependence on government incentives and policy exposure are substantive financial and operational concerns.
- Added Optical Communications segment as material profit driver and disclosed new cyclical risk: telecom/hyperscale capex spending volatility affecting demand.
See the full detail →
5 company-specific changes
fiscal period 2025-12-31
filed 2026-02-12
- Revenue concentration increased from 75% to 82%; Mounjaro/Zepbound concentration rose from 48% to 56%. Specific CVS Caremark delisting of Zepbound exemplifies realized formulary access risk.
- New voluntary pricing agreements with U.S. government announced November 2025; two additional products (Trulicity, Verzenio) selected for Medicare price controls effective 2028; expanded 340B program impact and Medicaid rebate calculation changes materially escalate pricing and revenue erosion risks.
See the full detail →
6 company-specific changes
fiscal period 2025-12-31
filed 2026-02-12
- Added disclosure of recently experienced increased material and component costs, plus acknowledgment that mitigation efforts may fail—escalates from generic risk to realized impact.
- Removal of detailed Airwave litigation and regulatory disclosures (CMA Charge Control, CAT appeal denial, High Court proceedings, $748M backlog contingency) represents material de-escalation of previously disclosed legal and financial risks.
See the full detail →